Key result
Wearable median nerve stimulation cuts recurrent atrial arrhythmia burden after AF ablation vs sham.
Why the study?
Autonomic modulation may improve rhythm outcomes after AF ablation without myocardial injury, but the effect of cutaneous median nerve stimulation after AF ablation was unknown.
Does non-invasive median nerve stimulation reduce atrial arrhythmia recurrence in patients after atrial fibrillation ablation?
RCT (n=77)
Double-blind
1:1
Yes
Does non-invasive median nerve stimulation reduce atrial arrhythmia recurrence in patients after atrial fibrillation ablation?
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Our vision is to extend what electrophysiologists can do for patients beyond the ablation procedure. Despite extraordinary advances in ablation and the work electrophysiologists are doing for patients, an efficacy glass ceiling remains. The NeuroPulse pilot provides a clinical signal that the next frontier in AF treatment may lie outside the heart itself, with non-invasive, wearable neuromodulation opening the possibility of an entirely new treatment category for electrophysiologists and their patients.”
“The NeuroPulse results provide an encouraging clinical signal that non-invasive, wearable neuromodulation following ablation may offer a fundamentally different way to approach that remaining challenge. These findings warrant confirmation in a larger multicentre clinical trial.”
Wearable median nerve stimulation may be a safe and effective nonablative adjunct to reduce recurrent atrial arrhythmias after atrial fibrillation ablation, pending larger confirmatory trials.
BACKGROUND: To improve atrial fibrillation (AF) ablation success, empirical lesions are often placed-with variable effectiveness-but at the expense of myocardial destruction. Autonomic modulation may provide a nonablative adjunct that improves rhythm outcomes without excess myocardial injury. OBJECTIVE: The purpose of this study was to evaluate cutaneous median nerve stimulation (MNS) after AF ablation. METHODS: NEUROPULSE was a 3-center, randomized, double-blind, sham-controlled pilot study. 77 patients were randomized 1:1 to active MNS (3 × 20-minute sessions/wk) or sham therapy; the modified intention-to-treat population included 59 patients (MNS: n = 31; sham: n = 28). Treatment began within 48 hours of ablation (largely pulsed field ablation) and continued for 6 months (daily for 2 weeks and then 3 times weekly). Surveillance included twice-daily 2-minute device electrocardiograms and 10-day patches at 2 and 6 months. RESULTS: The median age was 67 years (interquartile range 56-74 years); 39% were female, 68% had paroxysmal AF, and 27% underwent redo ablation. Blinding was maintained. During postblanking follow-up (months 2-6), 12 AF/atrial tachycardia/atrial flutter events occurred with MNS and 243 with sham (rate ratio 17.93; 95% confidence interval [CI] 10.04-32.0; P < .0001). After excluding 1 high-burden sham outlier, 12 vs 28 events occurred (rate ratio 2.17; 95% CI 1.10-4.27; P = .025). AF/atrial tachycardia/atrial flutter recurred in 2 of 31 patients who underwent MNS and 5 of 28 patients who underwent sham stimulation; 6-month arrhythmia-free survival was 90.0% vs 80.8%, respectively (hazard ratio 2.15; 95% CI 0.42-11.1; P = .36). Premature atrial contraction counts and patient-reported outcomes did not differ. No MNS- or device-related serious adverse events occurred. CONCLUSION: Wearable MNS after AF ablation was associated with fewer recurrent atrial arrhythmia events. This pilot study warrants confirmation in an adequately powered trial. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT06748157.
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2026) conducted an RCT in Atrial Fibrillation (n=77). Cutaneous median nerve stimulation (MNS) vs. Sham therapy was evaluated on AF/atrial tachycardia/atrial flutter events (Rate ratio 17.93, 95% CI 10.04-32.0, p=<0.0001). Wearable median nerve stimulation after atrial fibrillation ablation significantly reduced the burden of recurrent atrial arrhythmia events compared with sham (rate ratio 17.93; 95% CI 10.04-32.0; P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: